Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05703360
Other study ID # 22-5914
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 1, 2023
Est. completion date December 1, 2024

Study information

Verified date October 2023
Source University Health Network, Toronto
Contact Danielle Tchao
Phone 647-408-9638
Email danielle.tchao@uhn.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the effectiveness of an immersive virtual-reality (IVR) based stimulation program, in improving visual perception for people who have lost their driver's license due to perceptual or cognitive impairments. The main questions it aims to answer are: 1. Can the 6-week IVR stimulation program help improve driving performance? 2. Will participants experience improvement in visual detection and perception after training? Study Design Summary: - Participants will be randomized into a waitlist group or intervention-first group - The VR-based intervention will consist of training every 2 days for six weeks - Waitlist group will wait 6 weeks before starting intervention at study midpoint (week 7) - Intervention-first group will begin with intervention (week 1-6) and then stop intervention at study midpoint - Participants will complete tests related to driving performance, visual attention, and visual fields at the start of study, midpoint, and end of study Researchers will analyze data for changes from baseline in outcome measures.


Description:

This clinical trial will be an interventional, cross-over, single blind, randomized, supportive care, single-center study lasting 12 weeks with a target recruitment of 30 participants. SCREENING AND BASELINE TESTS Potential participants will be identified from patients receiving routine care at Toronto Western Hospital by their ophthalmologist. After obtaining informed consent and screened for inclusion, the research coordinator will set up appointments for each participant to complete baseline tests related to driving performance, visual attention, and visual fields. Participants will also practice the IVR program and be assessed for IVR sensitivity, or cybersickness, using the Virtual-Reality Induced Symptoms and Effects (VRISE) questionnaire. Participants will be randomized into a Waitlist group or Intervention-First group. The Intervention-First group will be given a head-mounted display (HMD) to take home for training. INTERVENTION (Week 1 - 12) Period 1 (Week 1-6): - Waitlist Group has no intervention - Intervention-First group trains at home every 2 days using HMD All participants are booked for their second appointments to repeat baseline tests once Period 1 is complete. Intervention-first group will return their HMD to the researchers and Waitlist group will be given their HMD to take home. Period 2 (Week 7-12) - Waitlist Group trains at home every 2 days using HMD - Intervention-First group has no intervention All participants are booked for their third appointments to repeat baseline tests once Period 2 is complete. Waitlist group will return their HMD to researchers. POST-INTERVENTION Analysis of outcome measures: 1. Period 1 (Waitlist Group vs Intervention-First Group) 2. Waitlist Group (Period 1 vs Period 2) 3. Intervention-First Group (Period 1 vs Period 2)


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date December 1, 2024
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender All
Age group 25 Years and older
Eligibility Inclusion Criteria: - Male and female > 25 years old. - Visual field defects due to TBI or stroke - BCVA = 20/50. - Previously held a valid driving license and were active drivers. - Ability to follow the visual and auditory stimuli and training instructions. - Online auditory test positive (-5dBHL to 60dBHL range) at 125 Hz (for research purposes only) - Home Wi-Fi access. Exclusion Criteria: - Both eyes with media opacity that impairs visual field testing. - Inability to perform during testing and training. - Cognitive/motor condition incompatible with driving simulator and/or VR. - Recreational or medicinal consumption of psychoactive drugs. - 3 consecutive VRISE scores < 25 at inclusion. - History of vertigo or dizziness. - Visual neglect. - Prior/current vision rehabilitation interventions. - Photosensitive epilepsy.

Study Design


Intervention

Device:
Audiovisual Stimulation
The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit. One or more of the spheres is temporarily highlighted (target). Then all 8 spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using the hand controller, the initially highlighted target(s) among the 8 spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased. Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)

Locations

Country Name City State
Canada KITE Research Institute, UHN Toronto Ontario
Canada Toronto Western Hospital Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

References & Publications (2)

Richards E, Bennett PJ, Sekuler AB. Age related differences in learning with the useful field of view. Vision Res. 2006 Nov;46(25):4217-31. doi: 10.1016/j.visres.2006.08.011. Epub 2006 Oct 5. — View Citation

Saredakis D, Szpak A, Birckhead B, Keage HAD, Rizzo A, Loetscher T. Factors Associated With Virtual Reality Sickness in Head-Mounted Displays: A Systematic Review and Meta-Analysis. Front Hum Neurosci. 2020 Mar 31;14:96. doi: 10.3389/fnhum.2020.00096. eCo — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Changes from baseline in braking response (sec) Driving performance will be assessed at the DriverLab, a driving simulator located at KITE-UHN under the supervision of the research team members. Initial visit (day 0), End of Period 1 (day 43), End of Period 2 (day 86)
Primary Changes from baseline in collisions (total #) Driving performance will be assessed at the DriverLab, a driving simulator located at KITE-UHN under the supervision of the research team members. Initial visit (day 0), End of Period 1 (day 43), End of Period 2 (day 86)
Primary Changes from baseline in lane keeping (meters of deviations/departures) Driving performance will be assessed at the DriverLab, a driving simulator located at KITE-UHN under the supervision of the research team members. Initial visit (day 0), End of Period 1 (day 43), End of Period 2 (day 86)
Primary Changes from baseline in speed variability (km/h) Driving performance will be assessed at the DriverLab, a driving simulator located at KITE-UHN under the supervision of the research team members. Initial visit (day 0), End of Period 1 (day 43), End of Period 2 (day 86)
Primary Changes from baseline in road rule violations (# and type) Driving performance will be assessed at the DriverLab, a driving simulator located at KITE-UHN under the supervision of the research team members. Initial visit (day 0), End of Period 1 (day 43), End of Period 2 (day 86)
Secondary Changes from baseline in visual attention and speed using Re:ViewD This vision test will be completed within the VR headset and will measure visual processing speed, sustained visual attention, and divided visual attention. This is a VR version of the Useful Field of View (UFoV) test which has been extensively used to measure visual attention in healthy individuals and older adults with low vision.
Outcome measures are time of display (ms) for 75% of correct responses.
Initial visit (day 0), End of Period 1 (day 43), End of Period 2 (day 86)
Secondary Changes from baseline in visual fields Visual fields are evaluated with the automated Humphrey Field Analysis III using Esterman binocular field test procedure at Toronto Western Hospital.
Outcome measures are number of points seen among 120 points.
Initial visit (day 0), End of Period 1 (day 43), End of Period 2 (day 86)
Secondary Simulator Sickness Questionnaire (SSQ) The SSQ will be administered after each driving session to capture any feelings related to simulator sickness.
The SSQ is a validated 16-item questionnaire that assesses various symptom categories of simulator sickness. Responses are made on a 4-point scale ranging from "not at all" (total score = 0) to "severe" (total score =235.62). A total score (TS) = 150 corresponds to mild to severe symptoms. Three subscales within the SSQ specifically targeting feelings of nausea (SSQ-N), oculomotor disturbances (SSQ-O), and disorientation (SSQ-D) as well as a total score (SSQ-TS) can be calculated based on pre-defined factor weightings.
Initial visit (day 0), End of Period 1 (day 43), End of Period 2 (day 86)
Secondary Virtual-Reality Induced Symptoms and Effects (VRISE) - initial screening This questionnaire is made up of five (5) questions related to possible cybersickness symptoms and will be completed within the VR headset by using the hand controller. Participants will complete the VRISE immediately after being trained on how to use the VR intervention at the initial visit. The VRISE score ranges from 5 (very intense level of symptoms and effects) to 35 (very low level of symptom and effects). Initial visit (day 0)
Secondary Virtual-Reality Induced Symptoms and Effects (VRISE) - intervention period This questionnaire is made up of five (5) questions related to possible cybersickness symptoms and will be completed within the VR headset by using the hand controller. Participants will complete the VRISE immediately after being trained on how to use the VR intervention at the initial visit. The VRISE score ranges from 5 (very intense level of symptoms and effects) to 35 (very low level of symptom and effects). Every other day with training session (Weeks 1-6 for Intervention-First Group, Weeks 7-12 for Waitlist Group)
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Recruiting NCT05993221 - Deconstructing Post Stroke Hemiparesis